척수손상환자에서 Alendronate 복용 후 골밀도의 증가 = The Increment of Bone Density in Patients with Spinal Cord Injuryafter Alendronate Therapy

다국어 초록 (Multilingual Abstract)

Objective: The aim of this study was to investigate the changes of bone mineral density (BMD) according to the postinjury duration, walking ability, and to assess the effect of oral alendronate therapy on BMD and biochemical markers in patients with spinal cord injury.
Method: Forty-eight subjects with spinal cord injury were enrolled. One tablet of AlendⓇ (10 mg of sodium alendronate) was administered daily for 6 months. After this, all subjects received placebo for 6 months as the same manner. The baseline quantitative assessments of BMD and biochemical bone markers, serum osteocalcin and C-terminal telopeptide of type I collagen (ICTP), were performed before the administration of drug. The follow up assess-ments were performed at 6 and 12 months after drug and placebo administration.
Results: The patients treated with oral alendronate showed significantly higher BMD of femur compared with baseline (p＜0.05). Also, ICTP showed significant reduction after alendronate therapy. BMD change rate of alendronate therapy was higher in functional ambulation group compared with wheelchair ambulation group. BMD change rate of alendronate therapy was higher than that of placebo administration.
Conclusion: Alendronate therapy may be useful in prevention of loss of BMD after spinal cord injury.

참고문헌 (Reference)

1 "척수손상 환자의 골다공증에 대한 Etidronate의 치료 효과" 21 : 867-873, 1997

2 "척수손상 환자에서 골대사지표와 골밀도의 변화" 27 : 894-898, 2003

3 "척수손상 환자에서 골 대사의 생화학적 변화" 21 : 1134-1140, 1997

4 "Use of bone bio-chemical markers with dual-energy x-ray absorptiometry for early determination of bone loss in persons with spinal cord injury" 51 : 958-963, 2002

5 "Quantitative histological data on disuse osteoporosis:comparison with biological data" 17 : 57-73, 1974

6 "Prevention of bone loss in paraplegics over 2 years with alendronate" 19 : 1067-1074, 2004

7 "Osteoporosis and risk of fracture in men with spinal cord injury" 39 : 208-214, 2001

8 "Osteoporosis after spinal cord injury" 10 : 371-378, 1992

9 "Osteoporosis after spinal cord injury" 36 : 822-825, 1998

10 "Lower extremity fractures after spinal cord injury:a retrospective study" 62 : 418-423, 1981

11 "Longitudinal study of bone turnover after acute spinal cord injury" 83 : 415-422, 1998

12 "Longitudinal study of bone mineral content in the lumbar spine the forearm and the lower extremities after spinal cord injury" 330-335, 1990

13 "Intravenous pamidronate attenuates bone density loss after acute spinal cord injury" 80 : 243-251, 1999

14 "Increased serum osteocalcin levels in patients with paraplegia" 30 : 204-209, 1992

15 "Effects of alendronate discontinuation on BMD in early postmenopausal women" 23 : 1998

16 "Early modifications of biochemical markers of bone metabolism in spinal cord injury patients.A preliminary study" 26 : 197-202, 1994

17 "Disuse osteoporosis" 48 : 147-156, 2001

18 "Cyclical etidronate:its effect on bone density in patients with acute spinal cord injury" 78 : 269-272, 1997

19 "Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilization.A review" 33 : 669-673, 1995

20 "Bone mass and endocrine adaptations to training in spinal cord injured individuals" 19 : 61-68, 1996

21 "Alendronate increases bone density in chronic spinal cord injury:a case report" 83 : 139-140, 2002